Fuzheng Kang’ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial

BACKGROUND: Patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) gene respond well to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. Chinese herbal medicine (CHM) has been used as a complementary therapy for cancer for deca...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiao-Bing, Wu, Wan-yin, Long, Shun-qin, Deng, Hong, Pan, Zong-Qi, He, Wen-Feng, Zhou, Yu-Shu, Liao, Gui-Ya, Li, Qiu-Ping, Xiao, Shu-Jing, Cai, Jiao-Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396173/
https://www.ncbi.nlm.nih.gov/pubmed/25873045
http://dx.doi.org/10.1186/s13063-015-0685-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396173/
https://www.ncbi.nlm.nih.gov/pubmed/25873045
http://dx.doi.org/10.1186/s13063-015-0685-2

Ejemplares similares